Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LCAR-B4822M

Cell therapy (CAR-T) · Kills target cells, directed at B-cell maturation antigen (TNFRSF17)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is LCAR-B4822M?

LCAR-B4822M is a CAR-T cell immunotherapy made from a patient's own peripheral blood mononuclear cells collected by leukapheresis and engineered to be given back by intravenous injection after lymphodepleting pre-treatment. It is studied in refractory or relapsed multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
B-cell maturation antigen (TNFRSF17) (antigen)
Mechanism
Kills target cells, directed at B-cell maturation antigen (TNFRSF17)
Therapy area
Oncology
In trials of
LEGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03674463 Phase 1 Refractory or Relapsed Multiple Myeloma Unknown LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Refractory or Relapsed Multiple Myeloma

Other drugs acting on TNFRSF17

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.